about
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition sProstate involvement in granulomatosis with polyangiitisRheumatology in Ukraine
P50
description
researcher
@en
wetenschapper
@nl
name
Roman Yatsyshyn
@en
Roman Yatsyshyn
@nl
type
label
Roman Yatsyshyn
@en
Roman Yatsyshyn
@nl
prefLabel
Roman Yatsyshyn
@en
Roman Yatsyshyn
@nl
P31
P496
0000-0003-1262-5609